Down 9.1% today, more than its biotech peers' 1.4%; no story names it yet.
Fell 37% since Oct 28
Down 37% from Oct 28 to Nov 10.
−3Long-term trend
Follow IONS's trial news. Pro members can get an alert when Ionis Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Moves 9.0% a day with no profit behind it |
| Its score | Down:Lowest Quality Score since Apr 2025 |
| Latest filing | 8-K, Nov 9 |
TodayNo story names it yet.
Mon Nov 16: UBS Global Biopharma Conference 2026Investor conference · date confirmed.
Expected to report Wed Feb 24, before the open
3 more dates ahead: conferences, for Pro members.
$1.9B in cash
No shelf registration or at-the-market program on file in the last three years.
An officer, Shannon L. Devers, sold 1,357 shares on Oct 16. 61 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
IONS is #265 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 265 |
Expected to report Wed Feb 24, before the open (in 106 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $243.0M, 55% more than a year ago; a loss of $0.66 a share, from $0.80.
“This increase was primarily driven by DAWNZERA product sales.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Commercial Revenue | $136M | – | $116M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 9)
| Measure | Figure |
|---|---|
| TRYNGOLZA product sales | about $50M |
Sales grew 5.3% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 2.8% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 9, 2026 | -18.1% | -21.4% | not yet |
| Jul 29, 2026 | -0.4% | -2.3% | -0.4% |
| Apr 29, 2026 | +0.4% | +4.3% | +4.8% |
Sales grew in four of the last seven years, to $944M in 2025. It made a profit in two of the eight years.
RSI 17.5, MACD below signal, below both averages. Not scored.
One insider bought $1.1M across 2 filings, and 2 insiders sold $61K across 2 filings, in the last 6 months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: IONS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
IONS scores -8 today, which Breakaway calls Poor. It is #265 of 281 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 37% from Oct 28 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
IONS scores -8 today, which Breakaway calls Poor (below zero). That is #265 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind IONS's -8.
One insider bought $1.1M across 2 filings, and 2 insiders sold $61K across 2 filings, in the last 6 months. The newest is Shannon L. Devers, EVP, Chief Human Resources Ofc, who sold $59K on Oct 16. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.